1. Home
  2. SII vs SYRE Comparison

SII vs SYRE Comparison

Compare SII & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprott Inc.

SII

Sprott Inc.

HOLD

Current Price

$147.67

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$39.85

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SII
SYRE
Founded
2008
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2011
2015

Fundamental Metrics

Financial Performance
Metric
SII
SYRE
Price
$147.67
$39.85
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$132.00
$55.57
AVG Volume (30 Days)
212.7K
693.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$26.22
N/A
Revenue Next Year
$11.39
N/A
P/E Ratio
$63.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$39.33
$10.91
52 Week High
$169.63
$45.76

Technical Indicators

Market Signals
Indicator
SII
SYRE
Relative Strength Index (RSI) 50.97 54.58
Support Level $79.37 $38.36
Resistance Level $167.47 $45.76
Average True Range (ATR) 7.95 1.93
MACD -1.76 -0.43
Stochastic Oscillator 6.12 28.37

Price Performance

Historical Comparison
SII
SYRE

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: